Artivion Inc (AORT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $931.88M
Last updated: Nov 17, 2026 at 11:04 AM ET
Artivion Inc (AORT) Earnings: Report Dates and Results
Artivion (AORT) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Artivion reported EPS of $0.08, below the $0.11 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AORT has an expected report date of Feb 10, 2027.
AORT Earnings Call
The latest AORT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, AORT beat 21, missed 11 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $123.79M, up 9.2% from $113.39M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.08 | $0.11 | $0.03 - $0.11 | -27.27% | Miss | -50.0% | 5 | 1 up, 5 down | Nov 5, 2026 | $123.79M |
| Jun 30, 2026 | $0.13 | $0.13 | $0.08 - $0.13 | 0.00% | In line | -45.8% | 6 | 0 up, 2 down | Aug 6, 2026 | $125.76M |
| Mar 31, 2026 | $0.08 | $0.12 | $0.06 - $0.20 | -33.33% | Miss | +33.3% | 6 | 2 up, 0 down | May 7, 2026 | $116.34M |
| Dec 31, 2025 | $0.17 | $0.18 | $0.14 - $0.21 | -5.56% | Miss | N/A | 5 | 1 up, 2 down | Feb 12, 2026 | $115.99M |
| Sep 30, 2025 | $0.16 | $0.15 | $0.13 - $0.19 | +6.67% | Beat | +33.3% | 5 | 3 up, 1 down | Nov 6, 2025 | $113.39M |
| Jun 30, 2025 | $0.24 | $0.11 | $0.09 - $0.16 | +118.18% | Beat | +242.9% | 4 | 1 up, 2 down | Aug 7, 2025 | $112.97M |
| Mar 31, 2025 | $0.06 | $0.05 | -$0.01 - $0.12 | +20.00% | Beat | 0.0% | 4 | 0 up, 1 down | May 5, 2025 | $98.98M |
| Dec 31, 2024 | -$0.39 | $0.04 | -$0.03 - $0.12 | N/A | N/A | -457.8% | 4 | 0 up, 0 down | Feb 24, 2025 | $97.31M |
| Sep 30, 2024 | $0.12 | $0.01 | N/A | N/A | N/A | +500.0% | 6 | 0 up, 0 down | Nov 7, 2024 | $95.78M |
| Jun 30, 2024 | $0.07 | $0.03 | N/A | +133.33% | Beat | +16.7% | 2 | 0 up, 0 down | Aug 8, 2024 | $98.02M |
| Mar 31, 2024 | $0.06 | $0.02 | N/A | +200.00% | Beat | +200.0% | 4 | 1 up, 0 down | May 6, 2024 | $97.43M |
| Dec 31, 2023 | $0.11 | -$0.10 | -$0.22 - -$0.04 | +210.00% | Beat | +10.0% | 4 | 0 up, 0 down | Feb 15, 2024 | $93.67M |
| Sep 30, 2023 | $0.02 | $0.03 | N/A | -33.33% | Miss | N/A | 5 | 0 up, 0 down | Nov 2, 2023 | $87.85M |
| Jun 30, 2023 | $0.06 | $0.02 | N/A | +200.00% | Beat | N/A | 5 | 0 up, 0 down | Aug 3, 2023 | $89.25M |
| Mar 31, 2023 | $0.02 | -$0.02 | N/A | +200.00% | Beat | -33.3% | 4 | 0 up, 0 down | May 4, 2023 | $83.23M |
| Dec 31, 2022 | $0.10 | -$0.02 | N/A | +600.00% | Beat | N/A | 5 | 0 up, 0 down | Feb 16, 2023 | $79.40M |
| Sep 30, 2022 | -$0.05 | -$0.04 | N/A | -25.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 3, 2022 | $76.84M |
| Jun 30, 2022 | -$0.03 | $0.03 | -$0.12 - $0.03 | -200.00% | Miss | -125.0% | 4 | 1 up, 0 down | Aug 4, 2022 | $80.34M |
| Mar 31, 2022 | $0.03 | -$0.01 | N/A | +400.00% | Beat | 0.0% | 4 | 0 up, 0 down | May 5, 2022 | $77.21M |
| Dec 31, 2021 | -$0.51 | $0.04 | N/A | N/A | N/A | -355.0% | 3 | 1 up, 0 down | Feb 17, 2022 | $79.39M |
| Sep 30, 2021 | -$0.03 | $0.03 | N/A | -200.00% | Miss | -123.1% | N/A | N/A | Nov 4, 2021 | $72.21M |
| Jun 30, 2021 | $0.12 | $0.07 | N/A | +71.43% | Beat | N/A | N/A | N/A | Jul 29, 2021 | $76.15M |
| Mar 31, 2021 | $0.03 | $0.10 | N/A | -70.00% | Miss | N/A | N/A | N/A | Apr 29, 2021 | $71.09M |
| Dec 31, 2020 | $0.20 | $0.03 | N/A | +566.67% | Beat | +100.0% | N/A | N/A | Feb 11, 2021 | $67.90M |
| Sep 30, 2020 | $0.13 | -$0.04 | N/A | +425.00% | Beat | +116.7% | N/A | N/A | Nov 4, 2020 | $65.13M |
| Jun 30, 2020 | -$0.02 | -$0.14 | N/A | +85.71% | Beat | -118.2% | N/A | N/A | Jul 30, 2020 | $53.77M |
| Mar 31, 2020 | -$0.08 | $0.02 | N/A | -500.00% | Miss | -300.0% | N/A | N/A | Apr 30, 2020 | $66.43M |
| Dec 31, 2019 | $0.10 | $0.08 | N/A | +25.00% | Beat | +100.0% | N/A | N/A | Feb 13, 2020 | N/A |
| Sep 30, 2019 | $0.06 | $0.06 | N/A | 0.00% | In line | -25.0% | N/A | N/A | Oct 30, 2019 | $67.88M |
| Jun 30, 2019 | $0.11 | $0.07 | N/A | +57.14% | Beat | +10.0% | N/A | N/A | Jul 30, 2019 | $142.28M |
| Mar 31, 2019 | $0.04 | $0.04 | N/A | 0.00% | In line | +100.0% | N/A | N/A | Apr 30, 2019 | $67.50M |
| Dec 31, 2018 | $0.05 | $0.11 | N/A | -54.55% | Miss | -54.5% | N/A | N/A | Feb 13, 2019 | $67.80M |
| Sep 30, 2018 | $0.08 | $0.07 | N/A | +14.29% | Beat | 0.0% | N/A | N/A | Oct 31, 2018 | $64.60M |
| Jun 30, 2018 | $0.10 | $0.07 | N/A | +42.86% | Beat | -16.7% | N/A | N/A | Aug 6, 2018 | $68.50M |
| Mar 31, 2018 | $0.02 | $0.03 | N/A | -33.33% | Miss | -77.8% | N/A | N/A | May 2, 2018 | $61.95M |
| Dec 31, 2017 | $0.11 | $0.11 | N/A | 0.00% | In line | -8.3% | N/A | N/A | Mar 7, 2018 | $52.83M |
| Sep 30, 2017 | $0.08 | $0.08 | N/A | 0.00% | In line | -38.5% | N/A | N/A | Oct 30, 2017 | $44.00M |
| Jun 30, 2017 | $0.12 | $0.10 | N/A | +20.00% | Beat | -7.7% | N/A | N/A | Jul 24, 2017 | $47.82M |
| Mar 31, 2017 | $0.09 | $0.04 | N/A | +125.00% | Beat | -10.0% | N/A | N/A | Apr 26, 2017 | $45.06M |
| Dec 31, 2016 | $0.12 | $0.09 | N/A | +33.33% | Beat | +33.3% | N/A | N/A | Feb 15, 2017 | $45.03M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.63, a profit after a loss of $0.14 per share the year before. It was $0.48 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.63 | N/A |
| Dec 31, 2024 | -$0.14 | -168.4% |
| Dec 31, 2023 | $0.21 | +320.0% |
| Dec 31, 2022 | $0.05 | N/A |
| Dec 31, 2021 | -$0.39 | -269.6% |
| Dec 31, 2020 | $0.23 | -25.8% |
| Dec 31, 2019 | $0.31 | +24.0% |
| Dec 31, 2018 | $0.25 | -37.5% |
| Dec 31, 2017 | $0.40 | -16.7% |
| Dec 31, 2016 | $0.48 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,100 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,145 | 11 | |
| 2026Q2 | Jun 30, 2026 | 6,671 | 11 | |
| 2026Q1 | Mar 31, 2026 | 6,498 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,655 | 4 | |
| 2025Q3 | Sep 30, 2025 | 6,319 | 11 | |
| 2025Q2 | Jun 30, 2025 | 5,292 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,462 | 10 | |
| 2024Q4 | Dec 31, 2024 | 7,625 | 10 |
2026Q3 Earnings Call
Opening remarks
Brian Johnston Host Good afternoon, and thank you for joining the call today. Joining me from Artivion's management team are Pat Mackin, CEO, and Lance Berry, COO and CFO. Before we begin, I would like to make the following statements to comply with the safe harbor requirements of the Private Securities Litigation Reform Act of 1995. Comments made on this call that look forward in time involve risks and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements made as to the company's or management's intentions, hopes, beliefs, expectations, or predictions of the future. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from these forward-looking statements. Additional information concerning certain risks and uncertainties that may impact these forward-looking statements is contained from time to time in the company's SEC filings, as well as the press release that was issued earlier today. You can also find a brief presentation with details highlighted on today's call on the Investor Relations section of the Artivion website. Lastly, I'd like to remind you to please refer to our press release published earlier today for information regarding our non-GAAP results, including a reconciliation of these results to our GAAP results. Unless otherwise stated, all of our comments on today's call will be using our non-GAAP results. Additionally, all percentage changes discussed will be on a year-over-year basis. Revenue growth rates will be the adjusted constant currency rates, and expenses as percentages of sales will be based on adjusted revenues. With that, I'll turn it over to the CEO, Pat Mackin.
Pat Mackin CEO Thanks, Brian, and good afternoon, everybody. In the third quarter, we delivered total constant currency revenue growth of 9% and an adjusted EBITDA decline of 8% year-over-year. These results reflect continued execution of our strategy designed to deliver long-term profitable growth through an expanding and clinically differentiated product portfolio. From a product category perspective, stent graft revenues grew 12% on a constant currency basis in the third quarter compared to the same period last year. This performance is consistent with the growth rate we reported in Q2, and notably, it came against a tougher AMDS prior-year comparison this quarter. On AMDS, the number of U.S. implants increased in the second quarter, which we believe reflects the impact of our recent PMA approval and our efforts to drive adoption of this new technology. We continue to view implant increases as the most important indicator of AMDS adoption, given that they reflect the real-world use and user experience that will drive growth in the long term. Meanwhile, U.S. AMDS set sales remain challenged.
Frequently Asked Questions About AORT
When is Artivion's next earnings date?
Artivion's next earnings report is expected for Feb 10, 2027.
Did AORT beat earnings estimates last quarter?
No. Artivion reported EPS of $0.08 for the quarter ended Sep 30, 2026, below the $0.11 estimate by 27.27%.
What EPS do analysts expect from AORT next quarter?
The consensus EPS estimate for Artivion for the quarter ending Dec 31, 2026 is -$0.05 from 11 analysts, with estimates from -$0.10 to $0.05.
How often does AORT beat earnings estimates?
Artivion beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +26.50%.
AORT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts